Voyager Therapeutics Inc
Voyager Therapeutics, Inc., a biotechnology company, focuses on the human genetics for the cure of neurological diseases. The company's lead product candidate is VY7523, an anti-tau antibody program for the treatment of alzheimer's disease (AD). Its product pipeline includes VY1706, a tau silencing gene therapy in preclinical trial for the treatment of alzheimer's disease; SOD1 silencing gene the… Read more
Voyager Therapeutics Inc (VYGR) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.141x
Based on the latest financial reports, Voyager Therapeutics Inc (VYGR) has a cash flow conversion efficiency ratio of -0.141x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-31.05 Million) by net assets ($219.82 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Voyager Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2013–2024)
This chart illustrates how Voyager Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Voyager Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Voyager Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Zhuzhou Feilu High-Tech Materials Co Ltd
SHE:300665
|
0.019x |
|
Nepes Corporation
KQ:033640
|
0.041x |
|
VGLIF
PINK:VGLIF
|
N/A |
|
Centuria Office REIT
AU:COF
|
0.021x |
|
SENCO GOLD LTD
NSE:SENCO
|
0.015x |
|
ProKidney Corp.
NASDAQ:PROK
|
-0.084x |
|
Medical Facilities Corporation
PINK:MFCSF
|
0.126x |
|
Genus Power Infrastructures Limited
NSE:GENUSPOWER
|
-0.083x |
Annual Cash Flow Conversion Efficiency for Voyager Therapeutics Inc (2013–2024)
The table below shows the annual cash flow conversion efficiency of Voyager Therapeutics Inc from 2013 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $299.76 Million | $-15.31 Million | -0.051x | -115.49% |
| 2023-12-31 | $236.32 Million | $77.92 Million | 0.330x | +255.57% |
| 2022-12-31 | $59.02 Million | $-12.51 Million | -0.212x | +62.36% |
| 2021-12-31 | $95.06 Million | $-53.52 Million | -0.563x | +10.15% |
| 2020-12-31 | $154.32 Million | $-96.72 Million | -0.627x | -228.15% |
| 2019-12-31 | $99.51 Million | $48.67 Million | 0.489x | +242.97% |
| 2018-12-31 | $46.45 Million | $-15.89 Million | -0.342x | +25.26% |
| 2017-12-31 | $134.05 Million | $-61.35 Million | -0.458x | -46.43% |
| 2016-12-31 | $135.92 Million | $-42.48 Million | -0.313x | -227.95% |
| 2015-12-31 | $169.07 Million | $41.30 Million | 0.244x | +102.35% |
| 2014-12-31 | $1.15 Million | $-11.92 Million | -10.372x | -829.50% |
| 2013-12-31 | $-3.83 Million | $-5.45 Million | 1.422x | -- |